Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 10/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305835 | 0.90 | TACR1 (0.60) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL5428179 | 0.86 | TACR1 (0.52) | TACR1MTORMLYCD | |
| SCHEMBL27732549 | 0.84 | MTOR (0.46) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL10200705 | 0.81 | CACNA1H (0.49) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL4874599 | 0.77 | MTOR (0.58) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL5670867 | 0.77 | CCR1 (0.48) | TACR1MTORMLYCDP2RX1TMPRSS4 | |
| SCHEMBL30661718 | 0.77 | MLYCD (0.65) | MLYCDCYP1A2CYP2D6CYP2C19L3MBTL1 | |
| SCHEMBL27385426 | 0.75 | TACR1 (0.42) | TACR1 | |
| SCHEMBL1695141 | 0.75 | MTOR (0.58) | MTORCYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL11306116 | 0.75 | TACR1 (0.63) | TACR1MTORMLYCDP2RX1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | TACR1 4222/4885MTOR 184/4885MLYCD 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.